Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction

Redfield, Margaret M.; Chen, Horng H.; Borlaug, Barry A.; Semigran, Marc J.; Lee, Kerry L.; Lewis, Gregory D.; LeWinter, Martin M.; Rouleau, Jean L.; Bull, David A.; Mann, Douglas L.; Deswal, Anita; Stevenson, Lynne W.; Givertz, Michael M.; Ofili, Elizabeth; O’Connor, Christopher M.; Felker, G. Michael; Goldsmith, Steven R.; Bart, Bradley A.; McNulty, Steven E.; Ibarra, Jenny C.; Lin, Grace; Oh, Jae K.; Patel, Manesh R.; Kim, Raymond J.; Tracy, Russell P.; Velazquez, Eric J.; Anstrom, Kevin J.; Hernandez, Adrian F.; Mascette, Alice M.; Braunwald, Eugene; Trial, for the RELAX

doi:10.1001/jama.2013.2024

articleJAMAMar 26, 2013Closed access

Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction

MMMargaret M. Redfield HHHorng H. Chen BABarry A. Borlaug MJMarc J. Semigran KLKerry L. Lee

Mayo Clinic · WinnMed

PubMed

Indexed incrossrefpubmed

Abstract

Importance

Studies in experimental and human heart failure suggest that phosphodiesterase-5 inhibitors may enhance cardiovascular function and thus exercise capacity in heart failure with preserved ejection fraction (HFPEF).

Objective

To determine the effect of the phosphodiesterase-5 inhibitor sildenafil compared with placebo on exercise capacity and clinical status in HFPEF.

Citation impact

1,127

total citations

FWCI: 77.11
Percentile: 100%
References: 32

Citations per year

Authors

31

Topics & keywords

Topics

Keywords

Medicine
Ejection fraction
Heart failure
Cardiology
Internal medicine
Placebo
Sildenafil
VO2 max

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.